Supplementary Material

Targeted Degradation of VEGFR2 by LYTACs Suppresses Angiogenesis and Tumor Growth

Rui Wang1 †, Yundi Ren1 †, Mingyan Liu1, Yuting Lou1, Guangyong Li1, Xiaohong Chu1 *, Dianlong Jia1 *, Jun Li1 *

1State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng 252059, China

†These authors contributed equally to this work.

***Corresponding Authors:**

Xiaohong Chu - State Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng 252059；Email: chuxiaohong@lcu.edu.cn

Dianlong Jia - State Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng 252059；Email: jiadianlong@lcu.edu.cn

Jun Li - State Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng 252059; Email: lijun1982@lcu.edu.cn



Cropped area for Figure 1.c

Supplementary Figure S1 Original uncropped SDS-PAGE gel for Figure 1c. Coomassie Blue-stained SDS-PAGE gel showing purified ZV2, ZV2-IGF2, and ZV2-EndoTag proteins. Lane M: protein molecular weight marker; lane 1: ZV2 (~14.9 kDa); lane 2: ZV2-IGF2 (~23.2 kDa); lane 3: ZV2-EndoTag (~30.1 kDa). The red box indicates the cropped area used in the main manuscript Figure 1c.



Cropped area for Figure 1.d

Supplementary Figure S2 Original uncropped Western blot for Figure 1d. Western blot analysis of purified ZV2, ZV2-IGF2, and ZV2-EndoTag using an anti-6×His antibody. Lane M: protein molecular weight marker; lane 1: ZV2; lane 2: ZV2-IGF2; lane 3: ZV2-EndoTag. The red box indicates the cropped area used in the main manuscript Figure 1d.



Cropped area for Figure 3.a

Supplementary Figure S3 Original uncropped Western blot for Figure 3a (ZV2-IGF2). Full-length membranes for VEGFR2 (top) and β-actin (bottom). HUVEC cells were treated with increasing concentrations of ZV2-IGF2 (0.1, 0.5, 1 μM) or left untreated. Lanes: M, marker; 1, control; 2, ZV2; 3, ZV2-IGF2 (0.1 μM); 4, ZV2-IGF2 (0.5 μM); 5, ZV2-IGF2 (1 μM). Red box indicates the cropped region used in Figure 3a.



Cropped area for Figure 3.a

Supplementary Figure S4 | Original uncropped Western blot for Figure 3a (ZV2-EndoTag). Full-length membranes for VEGFR2 (top) and β-actin (bottom). HUVEC cells were treated with increasing concentrations of ZV2-EndoTag (0.1, 0.5, 1 μM) or left untreated. Lanes: M, marker; 1, control; 2, ZV2; 3, ZV2-EndoTag (0.1 μM); 4, ZV2-EndoTag (0.5 μM); 5, ZV2-EndoTag (1 μM). Red box indicates the cropped region used in Figure 3a.



Cropped area for Figure 3.a

Supplementary Figure S5 | Original uncropped Western blot for Figure 3c. Comparison of VEGFR2 degradation by ZV2-IGF2 (1 μM) and ZV2-EndoTag (1 μM). Full-length membranes for VEGFR2 and β-actin. Lanes: M, marker; 1, control; 2, ZV2; 3, ZV2-IGF2; 4, ZV2-EndoTag. Red box indicates the cropped area used in Figure 3a.



Cropped area for Figure 4.a

Supplementary Figure S6 | Original uncropped Western blots for Figure 4a. Full-length membranes for p-AKT, p-MEK, and GAPDH. HUVEC cells were treated with ZV2, ZV2-IGF2, or ZV2-EndoTag (1 μM each). Lanes: 1, control; 2, ZV2; 3, ZV2-IGF2; 4, ZV2-EndoTag. Red boxes indicate the cropped regions used in Figure 4a.